AstraZeneca strikes $400 million Parkinson's drug deal with Takeda

LONDON (Reuters) - AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson's disease.